Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBIT (2019 - 2025)

Benitec Biopharma has reported EBIT over the past 7 years, most recently at -$13.4 million for Q4 2025.

  • Quarterly results put EBIT at -$13.4 million for Q4 2025, down 509.43% from a year ago — trailing twelve months through Dec 2025 was -$38.2 million (down 115.9% YoY), and the annual figure for FY2025 was -$41.8 million, down 85.7%.
  • EBIT reached -$13.4 million in Q4 2025 per BNTC's latest filing, down from -$9.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$2.2 million in Q4 2024 and bottomed at -$13.4 million in Q4 2025.
  • Median EBIT over the past 5 years was -$4.8 million (2021), compared with a mean of -$5.7 million.
  • The largest annual shift saw EBIT skyrocketed 68.31% in 2024 before it tumbled 509.43% in 2025.
  • Over 5 years, EBIT stood at -$4.8 million in 2021, then fell by 16.03% to -$5.6 million in 2022, then fell by 23.48% to -$6.9 million in 2023, then surged by 68.31% to -$2.2 million in 2024, then crashed by 509.43% to -$13.4 million in 2025.
  • Business Quant data shows EBIT for BNTC at -$13.4 million in Q4 2025, -$9.8 million in Q3 2025, and -$9.8 million in Q2 2025.